A Five Immune-Related lncRNA Signature as a Prognostic Target for Glioblastoma

Abstract

Background: A variety of regulatory approaches including immune modulation have been explored as approaches to either eradicate antitumor response or induce suppressive mechanism in the glioblastoma microenvironment. Thus, the study of immune-related long noncoding RNA (lncRNA) signature is of great value in the diagnosis, treatment, and prognosis of glioblastoma.Methods: Glioblastoma samples with lncRNA sequencing and corresponding clinical data were acquired from the Cancer Genome Atlas (TCGA) database. Immune-lncRNAs co-expression networks were built to identify immune-related lncRNAs via Pearson correlation. Based on the median risk score acquired in the training set, we divided the samples into high- and low-risk groups and demonstrate the survival prediction ability of the immune-related lncRNA signature. Both principal component analysis (PCA) and gene set enrichment analysis (GSEA) were used for immune state analysis.Results: A cohort of 151 glioblastoma samples and 730 immune-related genes were acquired in this study. A five immune-related lncRNA signature (AC046143.1, AC021054.1, AC080112.1, MIR222HG, and PRKCQ-AS1) was identified. Compared with patients in the high-risk group, patients in the low-risk group showed a longer overall survival (OS) in the training, validation, and entire TCGA set (p = 1.931e-05, p = 1.706e-02, and p = 3.397e-06, respectively). Additionally, the survival prediction ability of this lncRNA signature was independent of known clinical factors and molecular features. The area under the ROC curve (AUC) and stratified analyses were further performed to verify its optimal survival predictive potency. Of note, the high-and low-risk groups exhibited significantly distinct immune state according to the PCA and GSEA analyses.Conclusions: Our study proposes that a five immune-related lncRNA signature can be utilized as a latent indicator of prognosis and potential therapeutic approach for glioblastoma.

A Innovative Prognostic Symbol Based on Autophagy-Related Long Noncoding RNAs Signature Predicts in Low-Grade Glioma

“…It is concentrated in the cytoplasm of CRC cells and reversely regulates miR-1287-5p expression, which indicates adverse outcomes [49]. Recent studies have also shown that PRKCQ-AS1, as an immune-related lncRNA, provides a reliable prognostic indicator for glioblastoma patients [50]. (4) LINC00957 is signi cantly related to poor OS of CRC patients upon increased expression (P < 0.05), and inhibiting LINC00957 expression can reverse 5-FU resistance via P-gP down regulation [51].…”

Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics

“…Pearson coefficient (r) was applied to indicate the correlation between genes and reflect the biological relationship between the two genes. MTFR2 co-expressed genes were screened in 535 cases of LUAD tissues from TCGA via the R (version 3.6.1) [29]. Screening criteria: P < 0.001 and Pearson coefficient (r > 0.4 or r < − 0.4), were defined as moderate or above.…”

“…The genes were arranged according to the degree of differential expression by GSEA (version 4.0.1) to explore the effect of MTFR2 on each gene. Each analysis was repeated 1000 times [29,31]. Screening criteria: NOM p < 0.05.…”

Evolving Landscape of Long Non-coding RNAs in Cerebrospinal Fluid: A Key Role From Diagnosis to Therapy in Brain Tumors

“… Han et al (2020) reported that MIR22HG was a critical inducer of the Wnt/β-catenin signaling pathway for glioblastoma, and a specific small-molecule inhibitor, AC1L6JTK, could cause the inhibition of tumor growth in vivo . Interestingly, MIR22HG was also enlisted in an immune-related lncRNA signature associated with glioblastoma prognosis, indicating its pathophysiological complexity in this malignancy ( Li X. et al, 2021 ). Together, abundant evidence has revealed that lncRNAs play critical roles in multiple aspects of glioblastoma biology.…”